EyePoint, Inc. is under investigation by Pomerantz LLP for potential securities fraud following disappointing Phase 3 trial results for its drug DURAVYU™. The trial failed to meet its primary endpoint compared to a competitor drug, leading to a 66.98% drop in EyePoint's stock price on August 17, 2026. The investigation will determine if EyePoint and its executives engaged in unlawful business practices. Investors affected by the stock drop are encouraged to contact Pomerantz LLP for possible legal action.
EyePoint, Inc. is the subject of a legal investigation following its Phase 3 trial results. For readers following the health sector, here is Pluang's market snapshot as of Sep 17, 2026 21:11 WIB: out of 91 priced health-sector US stocks, 59 rose and 31 fell. Notable movers include SANA at USD 3.12 with a 6.85% increase, INO at USD 1.22 with a 6.09% increase, and ABCL at USD 12.38 with a 6.08% increase.
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
Fortrea Holdings Inc and Omico have formed a partnership to accelerate precision oncology research in Australia by connecting cancer patients to biomarker-driven clinical trials. The collaboration combines Fortrea's expertise in oncology clinical tri...
